Core Viewpoint - Pfizer Inc. is hosting a conference call on May 5, 2026, to discuss its First Quarter 2026 Performance Report, inviting both investors and the public to participate through a webcast [1][2]. Group 1: Conference Call Details - The conference call is scheduled for 10:00 a.m. EDT on May 5, 2026, and will provide updates on Pfizer's financial results [1]. - Participants can access the webcast and Performance Report via Pfizer's investor website, with registration recommended in advance [2]. - A replay of the webcast will be available within 24 hours after the live call and will remain accessible for at least 90 days [3]. Group 2: Company Overview - Pfizer is committed to applying science and global resources to develop therapies that significantly improve patients' lives, focusing on quality, safety, and value in healthcare products [4]. - The company collaborates with healthcare providers, governments, and communities to enhance access to affordable healthcare worldwide [4]. - Pfizer has a long history of 175 years in the biopharmaceutical industry, emphasizing its role in advancing wellness and combating serious diseases [4].

Core Insights - Pfizer Inc. and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide) for men with non-metastatic hormone-sensitive prostate cancer [1] Group 1 - The EMBARK study assessed XTANDI® in combination with leuprolide and as monotherapy [1] - The target patient population includes men with non-metastatic hormone-sensitive prostate cancer who have biochemical recurrence [1]